Positive data on Saniona’s SAN711 in epilepsy presented at SfN
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that positive preclinical data on Saniona’s lead ion-channel drug candidate and phase 2 ready asset, SAN711, will be presented at the annual meeting of the Society for Neuroscience (SfN) 11th-15th November 2023, Washington DC. The data shows strong suppression of absence seizures, which demonstrates that SAN711 represents a novel precision approach for treatment of non-convulsive generalized seizures.
Professor Vincenzo Crunelli, Cardiff University, U.K., has evaluated SAN711 in the highly predictive and translatable animal model for absence seizures, the GAERS rat model. SAN711 demonstrated robust dose-related suppression of Spike-Wave-Discharges (SWDs), which are the EEG manifestations of absence seizures supporting clinical efficacy in absence seizures. Saniona has replicated Professor Vincenzo Crunelli’s exciting findings in the GAERS rat model at the contract research laboratory, Synapcell (France), where SAN711 was administrated peroral and compared to valproate, which is used as first line therapy today.
“This data provides convincing evidence that SAN711 with its unique differentiated pharmacological profile can target the root cause of the disease pathophysiology without liability for attentional impairments and embryofetal risks. It is a truly precision approach, where SAN711 aborts the SWDs by modulating the GABA a3 containing receptors in brain circuits where the seizures are initiated and maintained resulting in a potential new treatment for various epilepsy patients with non-convulsive seizures including patients with childhood absence seizures, juvenile absence seizures and various type of pediatric epileptic syndromes. As SAN711 is not activating other GABAA receptors, it is anticipated to be much better tolerated as compared to other antiepileptic medications. This was clearly supported by the outcome of the phase 1 study reported last year,” said Karin Sandager Nielsen, CSO of Saniona.
SAN711 is a unique subtype selective activator of GABAA α3 receptors. A Phase 1 study in 2022 demonstrated that SAN711 is safe and well tolerated in humans[1]. A parallel Positron Emission Tomography (PET) biomarker study confirmed that it is possible to reach relevant receptor occupancies at well tolerated doses opening for continued clinical development of the asset.
“This new data supports the development of SAN711 as a precision medicine in patient populations suffering from generalized seizures. Over the last year, we have made significant progress in our two other programs, SAN2219 and Kv7, positioned for epilepsy. We now have three active programs within epilepsy and our deep understanding of ion channel function is a cornerstone for our novel approaches in this field,” said Thomas Feldthus, CEO of Saniona.
More about absence seizures
Absence epilepsy is very prevalent in younger children and adolescents, where it comprises up to 10% of all childhood epilepsies[2]. Even though the majority is well treated, >20% remains refractory[3] to treatment and 40% continue to have absence seizures into adulthood[4]. Additionally, 30% have inherent cognitive impairments[5], and as first line treatment is to adversely affect cognition[6], there is a significant medical significant need for improved treatment options devoid of the limitations associated with standard-of-care today.
[1] Topline data https://saniona.com/newsroom/single-press-release/?slug=saniona-reports-positive-top-line-results-from-the-san711-phase-1-clinical-trial-3148ba6f
[2] Albuja A and Khan G., Absence Seizure StatsPearls Oct. 2022
[3] Trinka E et al., J. Neurol. 2004
[4] Trinka E et al., Acta Neurol. Scand. 2005
[5] Masur D et al., Neurol. 2013
[6] Glauser T.A et al., NEJM 2010